The p53–Mdm2 system is key to tumor suppression. We have recently reported that p53 as well as Mdm2 are capable of supporting DNA replication fork progression. On the other hand, we found that Mdm2 is ...
Please provide your email address to receive an email when new articles are posted on . Administration of the MDM2 inhibitor milademetan in an intermittent dosing schedule mitigated dose-limiting ...
MDM2 has the capacity to interact with more than 100 proteins and macromolecules and the list is continuously increasing. The explanation for how a protein of 491 aa (amino acids) is able to display ...
Almost half of patients with advanced solid tumors or lymphomas experienced disease control with a drug that reactivates the TP53 tumor suppressor, a first-in-human study showed. Overall, the oral ...
Outside of breast cancer, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have not been as successful as tumors develop resistance. New research shows that a murine double minute (MDM2) ...
Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality. Targeting oncogenes and their interactive partners is an effective ...
Preclinical models highlight the potential of KT-253 as a monotherapy and combined with the standard of care agent venetoclax for the treatment of Acute Myeloid Leukemia (AML) MDM2 degraders shown to ...
Overexpression of c-met as a Prognostic Indicator for Transitional Cell Carcinoma of the Urinary Bladder: A Comparison With p53 Nuclear Accumulation PURPOSE: Testicular germ cell tumors (TGCTs) of ...
Please provide your email address to receive an email when new articles are posted on . Sandra D’Angelo, MD, discussed initial phase 1A/1B data from a clinical trial on the efficacy and safety of ...
Studying MDM2 inhibitors using Venetoclax (Venclexta) has led to unique responses in patients with acute myeloid leukemia (AML) and warrants wider and further study, according to data presented at the ...
A study has identified a possible second-line treatment for melanoma patients. A study from Vanderbilt-Ingram Cancer Center and the Department of Veterans Affairs led by Anna Vilgelm, MD, PhD, and Ann ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results